Detravenol, 1000 mg 18 pcs

Pharmacotherapeutic group: venotonic and venoprotective agent.

ATC code: C05CA53

Pharmacological properties
Pharmacodynamics
The drug is a purified micronized flavonoid fraction consisting of diosmin and other flavonoids converted into hesperidin. This combination has venotonic and angioprotective properties. It reduces venous distensibility and venous stasis, in the microcirculation – reduces capillary permeability and increases their resistance, improves indices of venous hemodynamics. It affects the following venous plethysmographic parameters: venous capacity, venous distensibility, time of venous emptying. The optimal effect is achieved when taking 1000 mg. The drug increases venous tone by reducing the time of venous emptying. In patients with signs of a pronounced microcirculatory disturbance an increase of capillary resistance is noted.
The effectiveness of the drug with respect to indicators of venous hemodynamics in the treatment of chronic diseases of the lower limbs veins and in the treatment of hemorrhoids is demonstrated.

Pharmacokinetics
Half-life is 11 hours.
The drug is actively metabolized, which is confirmed by the presence of phenolic acids in urine. It is excreted mainly through the intestine. The kidneys on average excrete about 14% of the taken dose of the drug.

Indications

Therapy of symptoms of chronic vein disease (elimination and relief of symptoms).

Therapy of symptoms of venous and lymphatic insufficiency:

• Pain;
• cramps in the lower extremities;
• feeling of heaviness and tumescence in the legs;
• “tired” legs.

Therapy for manifestations of venous-lymphatic insufficiency:

• edema of the lower extremities;
• trophic changes in the skin and subcutaneous tissue;
• venous trophic ulcers.

Symptomatic therapy of acute and chronic hemorrhoids.

Active ingredient

Purified micronized flavonoid fraction (diosmin, flavonoids in terms of hesperidin)

Composition

Active ingredient: purified micronized flavonoid fraction – 1000,000 mg, including: diosmin (90%) – 900,000 mg; flavonoids converted into hesperidin (10%) – 100,000 mg. Excipients: microcrystalline cellulose (MCC-101) – up to 1300,000 mg; sodium carboxymethyl starch – 54,000 mg; gelatin – 46,000 mg; magnesium stearate – 13,000 mg. Contents of the film film jacket: opadray II 85F240012 Pink – 40,000 mg, including: polyvinyl alcohol – 16,000 mg, macrogol 3350 – 9,752 mg, titanium dioxide – 8,080 mg, talc – 5,920 mg, iron oxide dye – 0,160 mg, iron oxide yellow dye – 0,088 mg.

How to take, the dosage

Ingestion.

The recommended dose for veno-lymphatic insufficiency is 1 tablet per day, preferably in the morning, with a meal. Tablets should be swallowed with water. For ease of swallowing it is possible to divide the tablet by the risk.

The duration of treatment may be several months (up to 12 months). If symptoms recur, the course of treatment may be repeated at the doctor’s recommendation.

The recommended dose for acute hemorrhoids is 3 tablets per day (1 tablet in the morning, afternoon and evening) for 4 days, then 2 tablets per day (1 tablet in the morning and evening) for the next 3 days.

The recommended dose for chronic hemorrhoids is 1 tablet a day.

Interaction

To date, no cases of drug interactions have been reported.

Special Instructions

Consult your doctor before taking Detravenol^®.

Prescribing Detravenol^® for exacerbations of hemorrhoids is not a substitute for specific treatment of other anal disorders.

The duration of treatment should not exceed the time stated in the section on Dosage and administration. If symptoms do not disappear after the recommended course of therapy, you should be seen by a proctologist, who will determine further therapy.

In the presence of venous circulatory disorders, the maximum effect of treatment is achieved by a combination of therapy with a healthy (balanced) lifestyle: it is advisable to avoid long periods of exposure to the sun, prolonged exposure to the sun, and reduction of excessive body weight. Walking and, in some cases, wearing special stockings helps to improve blood circulation.

Check with your doctor if symptoms do not decrease or get worse!

Do not exceed the maximum periods and recommended doses of the drug without consulting your doctor!

Synopsis

Oval biconvex convex film-coated tablets from pink to pale pink, with a rib on one side. A cross section of the tablets shows two layers: the core is gray-brown to gray-yellow with flecks of lighter and darker shades, and the film coating.

Contraindications

• High sensitivity to the drug’s components
• Breastfeeding period (experience of use is limited)

.

Side effects

The frequency of adverse effects is defined according to the WHO classification of adverse drug reactions by frequency of occurrence: very often – more than 1/10, frequently – more than 1/100 and less than 1/10, not often – more than 1/1000 and less than 1/100, seldom – more than 1/10000 and less than 1/1000, very rarelyless than 1/10000, including isolated cases; unknown frequency (the incidence of an adverse reaction cannot be determined from the available data).

Nervous system disorders: rarely – headache, dizziness, general malaise.

Gastrointestinal tract disorders: frequently – diarrhea, dyspepsia, nausea, vomiting; frequently – colitis; unspecified frequency – abdominal pain.

Dermal and subcutaneous fatty tissue disorders: rarely – skin rash, skin itching, urticaria; uncertain frequency – isolated swelling of the face, lips, eyelids; in exceptional cases – angioedema (Quincke’s edema).

If you experience or worsen the side effects mentioned in the instructions, or if you notice any other side effects not mentioned in the instructions, tell your doctor.